Amgen On The Offensive Against Roche’s EPO Mircera; Questions Safety Data
Executive Summary
Amgen is continuing its offensive against Roche's pending EPO product Mircera by signing an exclusive supply contract with a large dialysis provider and criticizing Roche's clinical trial program for the continuous erythropoietin receptor activator
You may also be interested in...
Roche/Amgen EPO Fight Gets Senate Hearing On Patent Defense Rules
The Senate Judiciary Committee is looking at whether to revise an obscure provision in patent law that could affect litigation between Amgen and Roche
Roche/Amgen EPO Fight Gets Senate Hearing On Patent Defense Rules
The Senate Judiciary Committee is looking at whether to revise an obscure provision in patent law that could affect litigation between Amgen and Roche
Mircera EPO Will Benefit From Lower Admin Costs Of Monthly Dosing – Roche
Monthly dosing for Roche's continuous erythropoietin receptor activator Mircera may make it attractive to providers because of the lower costs of administration associated with the extended dosing regimens, according to Pharmaceutical Division CEO William Burns